[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligos (Primer, Probe), Reagents), Type (Custom, Predesign), Application (Therapeutic (ASO, siRNA), Research (PCR), Diagnostic), End User (Hospital, Pharma, CROs) - Global Forecast to 2026

April 2029 | 237 pages | ID: O0BB67C32D0EN
MarketsandMarkets

US$ 4,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
The global oligonucleotide synthesis market is projected to reach USD 14.1 billion by 2026 from USD 6.3 billion in 2021, at a CAGR of 17.6% during the forecast period. The major factors driving the growth of this market include the increasing use of synthesized oligos in therapeutic applications, increasing government funding, and the growing focus on personalized medicine.

“By synthesized oligos product segment, the primers segmentaccounted for the fastest growing segment of theoligonucleotide synthesis market”

Based on product, the oligonucleotide synthesis market is segmented into oligonucleotide-based drugs, synthesized oligonucleotides, reagents, and equipment. By product, the synthesized oligonucleotides market is segmented into primers, probes, DNA oligos, RNA oligos, and other synthesized oligos such as BNA & LNA oligos. In 2020, the primers segment accounted for the fastest growing segment of this market, as they are used in various applications such as PCR, sequencing, gene synthesis, and cloning applications, among others.

“By therapeutic application, the antisense oligonucleotide-based therapies segment accounted for the largest share of theoligonucleotide synthesis market”

Based on application, the oligonucleotide synthesis market is segmented into therapeutic, research, and diagnostic applications. The therapeutic application segment is further segmented into Antisense oligonucleotide-based therapies, siRNAi oligonucleotide-based therapies, and CpG oligonucleotide-based therapies. IN 2020, antisense oligos accounted for the largest share of this segment as they form the basis of many therapies that are currently in clinical trials, thus boosting segment growth.

“Asia Pacific: The fastest-growing region in the oligonucleotide synthesismarket.”

The oligonucleotide synthesis market in the Asia Pacific region is projected to register the highest growth during the forecast period. Factors such as growing R&D funding, rising product availability, lower outsourcing costs, increasing research activities, increasing applications of oligos in molecular diagnostics & therapeutics, and the rising awareness of oligonucleotides are expected to drive market growth.

“North America: the largest share of the oligonucleotide synthesismarket”

North America accounted for the largest market share. The large share of this region can be attributed to the increasing R&D in life sciences, rising focus on improving the safety & quality of healthcare, rising demand for high-quality research tools for data reproducibility, and increasing focus on developing personalized therapeutics. The presence of many global players in this region is another key factor contributing to the large share of this market segment.

Breakdown of primaries

The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:
  • By Respondent– Supply Side- 80%, Demand Side-20%
  • By Designation— CXOs- 20%, Executives - 25%, Mangers - 55%
  • By Region— North America - 30%, Europe - 20%, APAC – 40%, RoW- 10%
The oligonucleotide synthesis market is dominated by a few globally established players such as Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Eurofins Scientific (Germany),Maravai Lifesciences (US), Agilent Technologies, Inc. (US), Bio-Rad Laboratories, Inc. (US), Microsynth AG (Switzerland), PolyGen GmbH (Germany), Metabion International AG (Germany), CSBio (US), TAG Copenhagen A/S (Denmark), Biolytic Lab Performance Inc. (US), Gene Link (US), Biogen Inc. (US), Sarepta Therapeutics, Inc. (US), Ionis Pharmaceuticals, Inc. (US), Jazz Pharmaceuticals, Inc. (US) Dynavax Technologies (US), and Alnylam Pharmaceuticals, Inc. (US).

Research Coverage:

The report segments the oligonucleotide synthesismarket based on region (Asia Pacific, Europe, North America, Latin America and Middle East and Africa), product(oligonucleotide-based drugs,

Synthesized oligonucleotides, reagents, and equipment), application(therapeutic, research and diagnostic), and end user (hospitals, pharmaceutical & biotechnology companies, academic research centers, diagnostic laboratories, and CROs and CMOs). The report also provides a comprehensive review of market drivers, restraints opportunities, challenges and trends in the oligonucleotide synthesismarket.

Key Benefits of Buying the Report:

The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the oligonucleotide synthesismarket and provides them information on key market drivers, restraints, challenges, and opportunities.
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
  1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
  1.3.1 MARKETS COVERED
  1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
  2.1.1 SECONDARY DATA
  2.1.2 PRIMARY DATA
FIGURE 1 BREAKDOWN OF PRIMARIES: OLIGONUCLEOTIDE SYNTHESIS MARKET
2.2 MARKET DATA ESTIMATION AND TRIANGULATION
FIGURE 2 DATA TRIANGULATION METHODOLOGY
2.3 MARKET ESTIMATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION- COMPANY REVENUE ANALYSIS-BASED ESTIMATION (RESEARCH AND DIAGNOSTIC MARKET)
FIGURE 4 MARKET SIZE ESTIMATION- COMPANY REVENUE ANALYSIS-BASED ESTIMATION (THERAPEUTIC MARKET)
FIGURE 5 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE (USD MILLION)
FIGURE 6 OLIGONUCLEOTIDE SYNTHES MARKET: FINAL CAGR PROJECTIONS (2021?2026)
FIGURE 7 OLIGONUCLEOTIDE SYNTHES: CAGR PROJECTIONS FROM THE ANALYSIS OF DEMAND-SIDE DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 8 OLIGONUCLEOTIDE SYNTHESIS: SEGMENTAL ASSESSMENT
2.4 INDUSTRY INSIGHTS
2.5 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY

FIGURE 9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2021 VS. 2026 (USD BILLION)
FIGURE 10 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION, 2020
FIGURE 11 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2021?2026
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE OLIGONUCLEOTIDE SYNTHESIS MARKET

4 PREMIUM INSIGHTS

4.1 OLIGONUCLEOTIDE SYNTHESIS MARKET OVERVIEW
FIGURE 13 INCREASING USE OF SYNTHESIZED OLIGOS IN THERAPEUTIC APPLICATIONS IS A KEY FACTOR EXPECTED TO DRIVE MARKET GROWTH
4.2 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION & COUNTRY (2020)
FIGURE 14 THERAPEUTIC APPLICATIONS ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2020
4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE
FIGURE 15 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES SEGMENT IS PROJECTED TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 16 OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  5.2.1 DRIVERS
    5.2.1.1 The increasing use of synthesized oligos in therapeutic applications
TABLE 1 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES (2016-2021)
FIGURE 17 ONGOING CLINICAL TRIALS BY TOP 10 THERAPEUTIC AREAS
    5.2.1.2 Increasing government investments for synthetic biology and genome projects
    5.2.1.3 Growing focus on personalized medicine
  5.2.2 RESTRAINTS
    5.2.2.1 Complexities associated with therapeutic oligos
  5.2.3 OPPORTUNITIES
    5.2.3.1 Key players in emerging economies
  5.2.4 CHALLENGES
    5.2.4.1 Delivery of oligonucleotide drugs to specific targets
5.3 THE IMPACT OF COVID-19 ON THE OLIGONUCLEOTIDE SYNTHESIS MARKET
TABLE 2 LIST OF PROBES AND PRIMERS USED FOR COVID-19 RESEARCH
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 18 DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
  5.4.1 KEY INFLUENCERS
5.5 PORTER’S FIVE FORCES ANALYSIS
TABLE 3 OLIGONUCLEOTIDE SYNTHESIS MARKET- PORTER’S FIVE FORCES ANALYSIS
  5.5.1 DEGREE OF COMPETITION
  5.5.2 BARGAINING POWER OF SUPPLIERS
  5.5.3 BARGAINING POWER OF BUYERS
  5.5.4 THREAT OF SUBSTITUTES
  5.5.5 THREAT OF NEW ENTRANTS
5.6 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS—MAXIMUM VALUE IS ADDED DURING THE MANUFACTURING PHASE
5.7 ECOSYSTEM ANALYSIS OF THE OLIGONUCLEOTIDE SYNTHESIS MARKET
FIGURE 20 ECOSYSTEM ANALYSIS OF THE OLIGONUCLEOTIDE SYNTHESIS MARKET
  5.7.1 ROLE IN THE ECOSYSTEM
5.8 TECHNOLOGICAL ANALYSIS
  5.8.1 SOLID-PHASE SYNTHESIS
  5.8.2 LIQUID-PHASE SYNTHESIS
5.9 REGULATORY ANALYSIS
  5.9.1 GOVERNMENT REGULATIONS FOR OLIGONUCLEOTIDE-BASED DRUGS:
  5.9.2 GOVERNMENT REGULATIONS FOR SYNTHESIZED OLIGONUCLEOTIDES: GOOD MANUFACTURING PRACTICE (GMP)
  5.9.3 ISO 13485
  5.9.4 IVD & ASR:
5.10 PATENT ANALYSIS
5.11 TRADE DATA
TABLE 4 IMPORT DATA FOR OLIGONUCLEOTIDES, BY COUNTRY, 2016–2020 (USD THOUSAND)
5.12 PRICING ANALYSIS

6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT

6.1 INTRODUCTION
TABLE 5 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
6.2 OLIGONUCLEOTIDE-BASED DRUGS
  6.2.1 OLIGONUCLEOTIDE-BASED DRUGS DOMINATED THE OLIGONUCLEOTIDE SYNTHESIS MARKET IN 2020
TABLE 6 LATE-STAGE OLIGONUCLEOTIDE-BASED THERAPIES
TABLE 7 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.3 SYNTHESIZED OLIGONUCLEOTIDES
TABLE 8 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2019–2026 (USD MILLION)
  6.3.1 SYNTHESIZED OLIGOS MARKET, BY PRODUCT
TABLE 9 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
    6.3.1.1 Primers
      6.3.1.1.1 Increasing applications for oligo primers in DNA sequencing and molecular diagnostics drive segment growth
TABLE 10 PRIMERS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 11 NORTH AMERICA: PRIMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 12 EUROPE: PRIMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 13 ASIA PACIFIC: PRIMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 14 LATIN AMERICA: PRIMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.3.1.2 Probes
      6.3.1.2.1 Probes are designed to detect various infectious agents
TABLE 15 PROBES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 16 NORTH AMERICA: PROBES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 17 EUROPE: PROBES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 18 ASIA PACIFIC: PROBES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 19 LATIN AMERICA: PROBES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.3.1.3 DNA oligos
      6.3.1.3.1 Innovations in DNA oligos that eliminate time-consuming PCR drives segment growth
TABLE 20 DNA OLIGOS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 21 NORTH AMERICA: DNA OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 22 EUROPE: DNA OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 23 ASIA PACIFIC: DNA OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 24 LATIN AMERICA: DNA OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.3.1.4 RNA oligos
      6.3.1.4.1 RNA oligos are widely used as molecular diagnostic tools
TABLE 25 RNA OLIGOS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 26 NORTH AMERICA: RNA OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 27 EUROPE: RNA OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 28 ASIA PACIFIC: RNA OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 29 LATIN AMERICA: RNA OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.3.1.5 Other synthesized oligos
TABLE 30 OTHER SYNTHESIZED OLIGOS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 31 NORTH AMERICA: OTHER SYNTHESIZED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 32 EUROPE: OTHER SYNTHESIZED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 33 ASIA PACIFIC: OTHER SYNTHESIZED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 34 LATIN AMERICA: OTHER SYNTHESIZED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
  6.3.2 SYNTHESIZED OLIGOS MARKET, BY TYPE
TABLE 35 SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
    6.3.2.1 Custom oligonucleotides
      6.3.2.1.1 The increasing requirement of custom oligonucleotides for clinical and preclinical research studies in the field of molecular biology and therapeutics is expected to drive
the market
TABLE 36 CUSTOMIZED OLIGOS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 37 NORTH AMERICA: CUSTOMIZED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 38 EUROPE: CUSTOMIZED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 39 ASIA PACIFIC: CUSTOMIZED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 40 LATIN AMERICA: CUSTOMIZED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.3.2.2 Predesigned oligos
      6.3.2.2.1 Predesigned oligos are widely used in routine research applications such as PCR and sequencing
TABLE 41 PREDESIGNED OLIGOS MARKET, BY REGION, 2019–2026(USD MILLION)
TABLE 42 NORTH AMERICA: PREDESIGNED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 43 EUROPE: PREDESIGNED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 44 ASIA PACIFIC: PREDESIGNED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 45 LATIN AMERICA: PREDESIGNED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4 REAGENTS
  6.4.1 THE GROWING APPLICATIONS OF OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS IS EXPECTED TO DRIVE THE MARKET GROWTH FOR REAGENTS
TABLE 46 REAGENTS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 47 NORTH AMERICA: REAGENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 48 EUROPE: REAGENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 49 ASIA PACIFIC: REAGENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 50 LATIN AMERICA: REAGENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.5 EQUIPMENT
  6.5.1 GROWTH IN THE EQUIPMENT MARKET IS MAINLY DRIVEN BY TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS
TABLE 51 EQUIPMENT MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 52 NORTH AMERICA: EQUIPMENT MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 53 EUROPE: EQUIPMENT MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 54 ASIA PACIFIC: EQUIPMENT MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 55 LATIN AMERICA: EQUIPMENT MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION

7.1 INTRODUCTION
TABLE 56 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
7.2 THERAPEUTIC APPLICATIONS
TABLE 57 THERAPEUTIC APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
  7.2.1 THERAPEUTIC APPLICATIONS MARKET, BY TYPE
  7.2.2 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES
    7.2.2.1 Antisense oligos form the basis of many therapies that are currently in clinical trials, thus boosting segment growth
  7.2.3 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES
    7.2.3.1 The ease of drug target identification with the help of bioinformatics is expected to drive segment growth
  7.2.4 CPG OLIGONUCLEOTIDE-BASED THERAPIES
    7.2.4.1 CpG ODNs have shown significant potential for the treatment of a wide variety of diseases, including cancer
TABLE 58 THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
7.3 THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE
  7.3.1 NEUROLOGICAL DISORDERS
    7.3.1.1 Neurological disorders dominated the therapeutic applications market by disease type in 2020
  7.3.2 INFECTIOUS DISEASES
    7.3.2.1 Antisense therapies and oligonucleotide aptamers have significant potential in the treatment & diagnosis of infectious diseases
  7.3.3 OTHER DISEASES
TABLE 59 THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2019–2026 (USD MILLION)
7.4 DIAGNOSTIC APPLICATIONS
TABLE 60 DIAGNOSTIC APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 61 NORTH AMERICA: DIAGNOSTIC APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 62 EUROPE: DIAGNOSTIC APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 63 ASIA PACIFIC: DIAGNOSTIC APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 64 LATIN AMERICA: DIAGNOSTIC APPLICATIONS, BY REGION, 019–2026 (USD MILLION)
7.5 RESEARCH APPLICATIONS
TABLE 65 RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 66 NORTH AMERICA: RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 67 EUROPE: RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 68 ASIA PACIFIC: RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 69 LATIN AMERICA: RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 70 RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
  7.5.1 PCR
    7.5.1.1 Increasing use of PCR in research to drive the market growth
TABLE 71 RESEARCH APPLICATIONS FOR PCR, BY REGION, 2019–2026 (USD MILLION)
TABLE 72 NORTH AMERICA: RESEARCH APPLICATIONS FOR PCR, BY REGION, 2019–2026 (USD MILLION)
TABLE 73 EUROPE: RESEARCH APPLICATIONS FOR PCR, BY REGION, 2019–2026 (USD MILLION)
TABLE 74 ASIA PACIFIC: RESEARCH APPLICATIONS FOR PCR, BY REGION, 2019–2026 (USD MILLION)
TABLE 75 LATIN AMERICA: RESEARCH APPLICATIONS FOR PCR, BY REGION, 2019–2026 (USD MILLION)
  7.5.2 SEQUENCING
    7.5.2.1 Advancements in sequencing technologies and the low cost of DNA sequencing to boost segment growth
TABLE 76 RESEARCH APPLICATIONS FOR SEQUENCING, BY REGION, 2019–2026 (USD MILLION)
TABLE 77 NORTH AMERICA: RESEARCH APPLICATIONS FOR SEQUENCING, BY REGION, 2019–2026 (USD MILLION)
TABLE 78 EUROPE: RESEARCH APPLICATIONS FOR SEQUENCING, BY REGION, 2019–2026 (USD MILLION)
TABLE 79 ASIA PACIFIC: RESEARCH APPLICATIONS FOR SEQUENCING, BY REGION, 2019–2026 (USD MILLION)
TABLE 80 LATIN AMERICA: RESEARCH APPLICATIONS FOR SEQUENCING, BY REGION, 2019–2026 (USD MILLION)
  7.5.3 OTHER RESEARCH APPLICATIONS
TABLE 81 OTHER RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 82 NORTH AMERICA: OTHER RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 83 EUROPE: OTHER RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 84 ASIA PACIFIC: OTHER RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 85 LATIN AMERICA: OTHER RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)

8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER

8.1 INTRODUCTION
TABLE 86 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
8.2 HOSPITALS
  8.2.1 INCREASING FDA-APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS DRIVES MARKET GROWTH FOR THE HOSPITALS SEGMENT
TABLE 87 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2019–2026 (USD MILLION)
8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  8.3.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY & THERAPEUTICS TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 88 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 89 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 90 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 91 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 92 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 DIAGNOSTIC LABORATORIES
  8.4.1 INCREASING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS IS EXPECTED TO DRIVE GROWTH OF THIS SEGMENT
TABLE 93 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 94 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 95 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 96 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 97 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
8.5 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS (CROS AND CMOS)
  8.5.1 CMOS AND CROS PROVIDE A WIDE RANGE OF CUSTOMIZED OLIGO SERVICES; KEY FACTOR DRIVING MARKET GROWTH
TABLE 98 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS AND CMOS, BY REGION, 2019–2026 (USD MILLION)
TABLE 99 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS AND CMOS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 100 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS AND CMOS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 101 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS AND CMOS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 102 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS AND CMOS, BY COUNTRY, 2019–2026 (USD MILLION)
8.6 ACADEMIC RESEARCH INSTITUTES
  8.6.1 ACADEMIC AND GOVERNMENT RESEARCHERS PRIMARILY USE OLIGOS FOR GENOMIC TECHNOLOGIES
TABLE 103 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
TABLE 104 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 105 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 106 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 107 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)

9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION

9.1 INTRODUCTION
TABLE 108 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2019–2026 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 21 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
TABLE 109 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 110 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 111 NORTH AMERICA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 112 NORTH AMERICA: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 113 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 114 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 115 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
  9.2.1 US
    9.2.1.1 Government initiatives and strategic developments by market players to drive market growth in the country
TABLE 116 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 117 US: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 118 US: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 119 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 120 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 121 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019-2026 (USD MILLION)
  9.2.2 CANADA
    9.2.2.1 Strong research infrastructure and the availability of funding to support market growth
TABLE 122 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 123 CANADA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 124 CANADA: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 125 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 126 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
TABLE 127 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019-2025 (USD MILLION)
9.3 EUROPE
TABLE 128 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 129 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 130 EUROPE: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 131 EUROPE: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 132 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 133 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
TABLE 134 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019-2026 (USD MILLION)
  9.3.1 GERMANY
    9.3.1.1 The presence of a large number of academic research institutes to support market growth in Germany
TABLE 135 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 136 GERMANY: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 137 GERMANY: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 138 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 139 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
TABLE 140 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
  9.3.2 FRANCE
    9.3.2.1 Government initiatives to strengthen R&D activities to propel market growth
TABLE 141 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 142 FRANCE: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 143 FRANCE: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 144 RANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 145 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
TABLE 146 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019-2026S (USD MILLION)
  9.3.3 UK
    9.3.3.1 Increasing strategic developments by market players in the field of oligonucleotide synthesis are supporting the growth of the market in the UK
TABLE 147 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 148 UK: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 149 UK: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 150 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 151 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
TABLE 152 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019-2026 (USD MILLION)
  9.3.4 ITALY
    9.3.4.1 Increasing research activities to drive the market for oligonucleotides synthesis in Italy
TABLE 153 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 154 ITALY: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 155 ITALY: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 156 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 157 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
TABLE 158 TALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019-2026 (USD MILLION)
  9.3.5 SPAIN
    9.3.5.1 Government initiatives to drive the market for oligonucleotide synthesis
TABLE 159 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 160 SPAIN: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 161 SPAIN: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 162 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 163 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
TABLE 164 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019-2026 (USD MILLION)
  9.3.6 ROE
TABLE 165 ROE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 166 ROE: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 167 ROE: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 168 ROE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 169 ROE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019-2026 USD MILLION)
TABLE 170 ROE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 22 APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
TABLE 171 APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 172 APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 173 APAC: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 174 APAC: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 175 APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 176 APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 177 APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
  9.4.1 CHINA
    9.4.1.1 The increasing focus of Chinese biopharma companies in this country is a major factor driving market growth
TABLE 178 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 179 CHINA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 180 CHINA: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 181 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 182 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 183 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
  9.4.2 JAPAN
    9.4.2.1 Various growth strategies adopted by key players in this region along with increasing awareness of oligos through conferences & workshops to drive the market growth in Japan
TABLE 184 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 185 JAPAN: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 186 JAPAN: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 187 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 188 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 189 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
  9.4.3 INDIA
    9.4.3.1 Strong initiatives to develop bio clusters and increasing adoption of genomic technologies is expected to aid market growth in India
TABLE 190 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 191 INDIA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 192 INDIA: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 193 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 194 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 195 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
  9.4.4 ROAPAC
TABLE 196 ROAPAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 197 ROAPAC: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 198 ROAPAC: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 199 ROAPAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 200 ROAPAC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 201 ROAPAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5 LATIN AMERICA
TABLE 202 LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 203 LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 204 LATAM: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 205 LATAM: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 206 LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 207 LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 208 LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
  9.5.1 BRAZIL
    9.5.1.1 Growing prevalence of infectious and non-infectious diseases to support market growth in Brazil
TABLE 209 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 210 BRAZIL: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 211 BRAZIL: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 212 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 213 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 214 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
  9.5.2 MEXICO
    9.5.2.1 Increasing research in synthetic biology to drive the market growth in Mexico
TABLE 215 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 216 MEXICO: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 217 MAXICO: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 218 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 219 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 220 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
  9.5.3 ROLATAM
TABLE 221 ROLATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 222 ROLATAM: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 223 ROLATAM: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 224 ROLATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 225 ROLATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 226 ROLATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
  9.6.1 THE GROWING ACCEPTANCE OF PERSONALIZED MEDICINE IS EXPECTED TO DRIVE MARKET GROWTH FOR OLIGOS
TABLE 227 MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 228 MEA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 229 MEA: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 230 MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 231 MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 232 MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS
FIGURE 23 OLIGONUCCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS (RESEARCH AND DIAGNOSTIC MARKET), BY KEY PLAYER, 2020
FIGURE 24 OLIGONUCCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS (FOR THERAPEUTICS MARKET), BY KEY PLAYER, 2020
10.3 MARKET RANKING ANALYSIS
FIGURE 25 COMPANY RANKING IN THE OLIGONUCLEOTIDE SYNTHESIS MARKET, 2020 (RESEARCH AND DIAGNOSTIC MARKET)
10.4 MARKET EVALUATION FRAMEWORK
TABLE 233 MARKET EVALUATION FRAMEWORK: PRODUCT LAUNCHES AND APPROVALS— MAJOR STRATEGY ADOPTED BY MARKET PLAYERS
10.5 MARKET REVENUE ANALYSIS
FIGURE 26 REVENUE ANALYSIS OF TOP 5 PLAYERS (2016–2020) (THERAPEUTICS MARKET)
10.6 COMPANY PRODUCT FOOTPRINT
TABLE 234 PRODUCT PORTFOLIO ANALYSIS: OLIGONUCLEOTIDE SYNTHESIS MARKET
10.7 COMPANY APPLICATION FOOTPRINT
TABLE 235 APPLICATION ANALYSIS: OLIGONUCLEOTIDE SYNTHESIS MARKET
10.8 COMPANY GEOGRAPHIC FOOTPRINT
TABLE 236 GEOGRAPHIC ANALYSIS: OLIGONUCLEOTIDE SYNTHESIS MARKET
10.9 COMPETITIVE SCENARIO
  10.9.1 KEY PRODUCT LAUNCHES
  10.9.2 DEALS
  10.9.3 OTHER DEVELOPMENTS

11 COMPANY EVALUATION MATRIX

11.1 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX (RESEARCH AND DIAGNOSTIC MARKET) (2020)
  11.1.1 STARS
  11.1.2 EMERGING LEADERS
  11.1.3 PERVASIVE PLAYERS
  11.1.4 PARTICIPANTS
FIGURE 27 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC): COMPANY EVALUATION MATRIX, 2020
11.2 COMPANY EVALUATION MATRIX (THERAPEUTICS MARKET) (2020)
  11.2.1 STARS
  11.2.2 EMERGING LEADERS
  11.2.3 PERVASIVE PLAYERS
  11.2.4 EMERGING COMPANIES
FIGURE 28 COMPETITIVE LEADERSHIP MAPPING: OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTICS)

12 COMPANY PROFILES

12.1 MAJOR PLAYERS
(Business Overview, Products/Solutions Offered, Recent Developments, Right to Win)*
  12.1.1 DANAHER CORPORATION
FIGURE 29 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
  12.1.2 THERMO FISHER SCIENTIFIC, INC.
FIGURE 30 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
  12.1.3 MERCK KGAA
FIGURE 31 MERCK KGAA: COMPANY SNAPSHOT (2020)
  12.1.4 EUROFINS SCIENTIFIC
FIGURE 32 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2020)
  12.1.5 LGC LIMITED
FIGURE 33 LGC LIMITED: COMPANY SNAPSHOT (2020)
  12.1.6 MARAVAI LIFESCIENCES
FIGURE 34 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2020)
  12.1.7 AGILENT TECHNOLOGIES, INC.
FIGURE 35 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020)
  12.1.8 KANEKA CORPORATION
FIGURE 36 KANEKA CORPORATION: COMPANY SNAPSHOT (2019)
  12.1.9 BIOLEGIO B.V.
  12.1.10 BIOLYTIC LAB PERFORMANCE INC.
  12.1.11 MICROSYNTH AG
12.2 OTHER PLAYERS
  12.2.1 ADTBIO LTD.
  12.2.2 TWIST BIOSCIENCE CORPORATION
  12.2.3 ETON BIOSCIENCE, INC.
  12.2.4 CSBIO
  12.2.5 TAG COPENHAGEN A/S
12.3 THERAPEUTIC PLAYERS
  12.3.1 BIOGEN INC.
FIGURE 37 BIOGEN: COMPANY SNAPSHOT (2020)
  12.3.2 SAREPTA THERAPEUTICS, INC.
FIGURE 38 SAREPTA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2020)
  12.3.3 IONIS PHARMACEUTICALS, INC.
FIGURE 39 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2020)
  12.3.4 ALNYLAM PHARMACEUTICALS, INC.
FIGURE 40 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2020)
*Business Overview, Products/Solutions Offered, Recent Developments, Right to Win might not be captured in case of unlisted companies.

13 APPENDIX

13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS

In the coming five years, growth in the oligonucleotide synthesis market is likely to be centered on China, Malaysia, Singapore, and India. This can be attributed to the growing availability of synthesized oligos along with an increase in the R&D funding and activities in the APAC region. Furthermore, increasing focus of prominent players in the APAC market is another factor driving the growth of this market. For instance, in July 2013, Integrated DNA Technologies, Inc. (IDT) opened an oligonucleotides manufacturing facility in Singapore to cater to the research companies in the APAC region, thereby establishing its footprint in the APAC market. Such developments are likely to spur the growth of the APAC oligonucleotide synthesis market in the coming years.

The key strategies followed by most companies in the oligonucleotide synthesis market are new product launches; agreements, collaborations, and partnerships; mergers and acquisitions; and expansions. Of all the growth strategies adopted by players in this field, agreements, collaborations, and partnerships accounted for the largest share of XX% of the overall growth strategies from 2010 to 2014. Some leading players adopting these strategies are BioAutomation Corporation (U.S.), Eurofins Genomics (Germany), and GE Healthcare (U.K.). Expansions accounted for the second-largest share of XX% of the overall growth strategies adopted by the players in the market.

The prominent players in the oligonucleotide synthesis market are Agilent Technologies, Inc. (U.S.), BioAutomation Corporation (U.S.), BioSearch Technologies, Inc. (U.S.), Eurofins Genomics (Germany), Eurogentec (Belgium), GE Healthcare (U.K.), Glen Research (U.S.), Gene Link, Inc. (U.S.), GenScript USA Inc. (U.S.), GeneDesign, Inc. (Japan), Integrated DNA Technologies, Inc. (IDT) (U.S.), Link Technologies, Ltd. (U.K.), Nitto Denko Avecia, Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), and TriLink BioTechnologies, Inc. (U.S.).

North America commands the largest share of the global oligonucleotide synthesis market, followed by Europe. However, the European oligonucleotide synthesis market is expected to grow at a slower pace as compared to North America due to the Eurozone debt crisis. The Asia-Pacific market, on the other hand, is in the growth phase and is the fastest-growing region in the global oligonucleotide synthesis market. The growth in the APAC oligonucleotide synthesis market is likely to be centered at China, Malaysia, Singapore, and India. This can be attributed to the growing availability of synthesized oligos and the increase in R&D funding and activities in the APAC region. Furthermore, increasing focus of prominent players on the APAC region is another factor driving the growth of this market.

Oligonucleotide synthesis is a highly commoditized market. With its rising attractiveness, an increasing number of companies are moving into this niche market, resulting in price pressure. Oligos have been branded as relatively more expensive research tools as compared to other life sciences research tools. This is further restricting the industry growth, as there are certain limitations related to increasing the cost of oligos. This factor is making it difficult for market players to survive and/or grow at a faster and desired pace. However, market consolidation in the coming years can bring price enhancement in this industry.

The importance of synthetic oligonucleotides as therapeutic drugs for treating diseases has grown significantly over the last decade. Some of the major driving factors for this growth are characterization of more targets following the identification of the human genome, advancements in antisense oligonucleotides, and the development of double stranded small interfering RNA (siRNA). Therapeutic oligos can either be single stranded such as antisense oligonucleotides or double stranded such as siRNA. Furthermore, therapeutic oligos can be useful in treating diseases ranging from viral infections, respiratory diseases, and cancer to rare diseases such as Duchenne Muscular Dystrophy (DMD), Cystic Fibrosis, and Thrombic Thrombocytopenic Purpura.

Currently, only two oligonucleotide-based drugs, namely, Vitravene and Macugen have received market approval and a large number of oligonucleotide-based drugs are in various stages of clinical development in the U.S., Canada, Europe, and other parts of the world. As of 2011, there were over XX oligonucleotide-based drugs in clinical development in the U.S., Europe, and Canada; some of these include antisense oligonucleotides, immunostimulatory oligonucleotides, DNA duplex decoys, siRNAs, ribozymes, microRNAs, aptamers, and spiegelmers. Although most oligonucleotides in clinical development are chemically similar, the mechanisms of their action vary widely. As a result, the development of a unified set of regulatory guidelines that can effectively address the safety and quality requirements for such a diverse group of molecular entities with various unique mechanisms of action is a challenging task.

There are no formal regulatory guidelines available from any regulatory agency for the development of this class of therapeutics. It has been a general practice for regulatory agencies to apply guidelines proposed for small molecules to oligonucleotide therapeutics, owing to their similar characteristics. These include all quality-related regulatory guidelines issued by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Thus, there is a need to address the basic regulatory issues regarding the chemistry, manufacturing, and control of drugs and products belonging to this unique class of therapeutics.



More Publications